Employers are facing unprecedented challenges in managing the complexities of pharmaceutical benefits, particularly with emerging therapies like gene and cell treatments. These cutting-edge therapies offer hope and new possibilities for treating conditions previously deemed untreatable, but they also make benefits plans increasingly complicated to manage.
During this webinar you’ll learn how to best position your organization financially while ensuring that every member facing a complex healthcare journey has the resources and support they need.
Join us to explore:
- The impact of gene and cell treatments and how they will affect your organization
- The benefits and challenges associated with using value-based care for high-cost therapies
- Why comprehensive healthcare navigation is essential for members with complex conditions
Panelists
Quantum Health
Quantum Health
Quantum Health
More like this
Balancing the Clinical Benefits and Cost of GLP-1s
Join us for an in-depth look at GLP-1 medications, including how they work, why they’re so popular, and the risks associated with taking them. Together we’ll explore strategies to help employers manage the use of these drugs within their benefits plan while also examining medical trends associated with GLP-1s. You’ll leave with insights to help set your organization up for long-term success, both clinically and financially.
Learn moreBuilding Bridges to Health Equity: Unveiling the Link Between Year-Round Member Support and Care Access
Watch our partnered webinar with RISE, as we share thought leadership on the latest strategies for enhancing member experience, improving satisfaction, and closing care gaps.
Learn moreNavigating the MSK Epidemic
In this thought-leadership webinar, industry experts will unpack the musculoskeletal (MSK) epidemic and share innovative ideas about managing the rising cost of care. Featuring insights from top MSK experts across the healthcare industry, this session will explore practical strategies to enhance care while reducing the administrative burden.
Learn more